Group 1: Globalization Strategy - The company is transitioning its globalization strategy from "product-based/opportunistic expansion" to a "structured operational globalization phase" focusing on building systems and improving operational quality rather than just increasing sales [3] - Key markets for expansion include the United States and developing countries, with a focus on establishing localized operational capabilities and tailored marketing strategies [2][3] - The company aims to enhance its product offerings by moving from POCT to IVD, thereby achieving a richer product range and higher-level terminal breakthroughs [3] Group 2: Resource Allocation and Capabilities - Increased R&D investment and strengthening of overseas teams are planned to support the vision of becoming a globally trusted IVD enterprise [3] - Core capabilities for the globalization 2.0 phase include a self-controlled compliance registration system covering key countries, operational closed-loop capabilities, and enhanced delivery and service capabilities [3] - The company plans to establish subsidiaries in key countries like Russia and the Philippines by 2025, focusing on service and sales-oriented structures [4][6] Group 3: Product Line and Market Position - The international department's product lines include traditional products (gold standard and fluorescence) and emerging products (single-use luminescence, tube luminescence, electrochemical blood gas) [4][5] - The company has a strong position in the U.S. market for toxicology testing, with plans to optimize product structures and improve profitability through higher-margin respiratory infectious disease products [5][6] - The expected market size for core developing countries, excluding North America, is approximately $3 billion, with a low current market share [6] Group 4: Financial Performance and Growth Projections - Profit growth is expected to outpace revenue growth, driven by higher margins from respiratory infectious disease products compared to traditional lines [7][8] - The company anticipates maintaining stable gross margins while absorbing price pressures through cost reductions and the introduction of new product lines [7][8] - The international department's chemical luminescence business is positioned for growth, with a strategic focus on both single-use and tube products entering international markets [8][9] Group 5: Vision and Future Outlook - The company is committed to expanding into the IVD market driven by innovation and AI, with a clear vision of becoming a globally trusted IVD enterprise [9] - Strengthening brand and service systems is essential for building confidence in international markets, supported by a robust product portfolio and enhanced product capabilities [9]

Group 1: Globalization Strategy - The company is transitioning its globalization strategy from "product-based/opportunistic expansion" to a "structured operational globalization phase" focusing on building systems and improving operational quality rather than just increasing sales [3] - Key markets for expansion include the United States and developing countries, with a focus on deepening core market penetration [2] - The company aims to establish a compliant registration system covering key countries in Europe, Latin America, and others to enhance market access and reduce compliance risks [3] Group 2: Product Development and Upgrades - The company plans to shift from POCT to IVD products globally, enhancing product diversity and achieving higher-level terminal breakthroughs [3] - New product lines include single-use luminescence and tube-based luminescence, with certifications expected in 2025 and 2026, targeting both high-level laboratories and grassroots medical systems [4] - The company is also focusing on developing a pathology strategy that starts with developed countries and expands to developing nations, with certifications expected in 2025 and 2026 [4] Group 3: Financial Performance and Growth - The company anticipates that profit growth will outpace revenue growth in the next two to three years, driven by higher margins from respiratory infectious disease products compared to traditional lines [7] - The international department's revenue potential in core developing countries is estimated at approximately $3 billion, with a low current market share [6] - The company aims to maintain stable gross margins while absorbing price pressures through cost reductions and improving product line growth [7] Group 4: Market Position and Competitive Advantages - The company has over 20 years of overseas market experience, providing advantages in registration, channels, teams, and brand recognition [6] - Compared to Korean manufacturers, the company benefits from production advantages due to the large Chinese market [6] - The company has established a strong position in the U.S. market with a comprehensive product line and effective market coverage, emphasizing channel control and profit management [6]

Summary of the Conference Call for Wanfu Biology Company Overview - **Company**: Wanfu Biology - **Industry**: In Vitro Diagnostics (IVD) Key Points Global Strategy and Market Expansion - The global strategy has evolved from a product-focused approach (1.0) to a system-oriented operation (2.0), emphasizing the establishment of local operational models and compliance to enhance profitability quality [2][4] - The international department is expected to achieve a compound annual growth rate (CAGR) of 30% over the next five years, with the U.S. subsidiary projected to grow at approximately 25%-30% [2][20] - The company aims to expand its product lines in the overseas market, including luminescence, pathology, molecular diagnostics, and blood gas testing [2][5] Product Line Development - The luminescence business is expected to generate around $10 million in revenue by 2025, with a target of reaching $60 million in five years at a CAGR of 40%-50% [2][4] - The respiratory infectious disease segment in the U.S. is identified as a core growth area, with a market potential of $1.7 billion, anticipated to significantly boost performance from 2026 to 2027 [2][4] - The pathology and molecular diagnostics segments are prioritizing entry into developed countries, with successful validation of immunohistochemistry products in Europe [2][8] Localization and Risk Management - The company is accelerating its "major country strategy," planning to establish subsidiaries in India, Saudi Arabia, and Brazil by 2026 to enhance local market penetration [2][4] - To mitigate geopolitical risks, multiple logistics plans (A/B/C) have been established, ensuring delivery through alternative routes such as Turkey [2][28] Internationalization Framework - The framework for deepening internationalization in 2026 focuses on sustainable development in overseas markets, leveraging 30 years of technological accumulation and enhancing local operational capabilities [3][4] - The company plans to transition from product export to localized operations, gradually deepening market engagement [3][4] Competitive Landscape - The U.S. market is characterized by competition from domestic peers like Jiuwan and Dongfang, with the company maintaining a comprehensive product layout and strong channel control [20][21] - The company has established a solid foundation in the U.S. market, with a focus on respiratory infectious diseases, toxicology, and pregnancy testing [15][18] Financial Performance and Projections - The international department's gross margin is approximately 60%, with a sales and marketing expense ratio of about 15% [22] - The U.S. subsidiary's profit growth is expected to outpace revenue growth, driven by a lightweight business model and high margins in the respiratory infectious disease product line [24] Future Outlook - The company anticipates a 30% CAGR for its international business over the next five years, with the U.S. subsidiary expected to grow at 25%-30% [20][29] - The strategic focus will remain on innovation and AI-driven solutions, aiming to become a globally trusted IVD enterprise [29] Additional Insights - The company is actively pursuing partnerships with international IVD firms and has established R&D teams in the U.S. and Japan to support its internationalization efforts [21] - The market potential for IVD in developing countries is significant, with a focus on countries with GDP over $5,000 and populations exceeding 100 million [22][23] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting the company's growth trajectory, product development, and market positioning within the IVD industry.

| 名称 | 注册证号 | | 有效期至 | 预期用途 | | --- | --- | --- | --- | --- | | 抑制素 B 测定试剂盒 | | | | 用于体外定量测定人血清、血浆的抑制素 B | | （化学发光免疫分析 | 粤 械 | 注 | 准 2031/02/03 | （Inhibin B，INH B）的含量。临床上用于睾丸生 | | | 20262400173 | | | | | 法） | | | | 精功能和女性卵巢储备功能的辅助诊断。 | | 胃泌素 测定试剂 17 | | | | 用于体外定量测定人血清、血浆中胃泌素 17 | | | 粤 械 | 注 | 准 | | | 盒（化学发光免疫分 | 20262400008 | | 2031/01/05 | （G-17）的 含量。临床上用于萎缩性胃炎的辅助 | | 析法） | | | | 诊断。 | | 甲状腺球蛋白测定试 | 粤 械 | 注 | 准 | 用于体外定量测定人血清、血浆中甲状腺球蛋白 | | 剂盒（化学发光免疫 | | | 2030/12/29 | （Tg） 的含量。临床上主要用于甲状腺疾病的辅 | | 分析法） | 20 ...

二零二六年三月 | 北京总部 | 电话: | (86-10) 8519-1300 | 上海分所 | 电话: (86-21) | 5298-5488 | 广州分所 | 电话: (86-20) 2805-9088 | 深圳分所 | 电话: (86-755) 2939-5288 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 传真: | (86-10) 8519-1350 | | 传真: (86-21) | 5298-5492 | | 传真: (86-20) 2805-9099 | | 传真: (86-755) 2939-5289 | | 杭州分所 | 电话: | (86-571) 2689-8188 | 成都分所 | 电话: (86-28) | 6739-8000 | 西安分所 | 电话: (86-29) 8550-9666 | 青岛分所 | 电话: (86-532) 6869-5000 | | | 传真: | (86-571) 2689-8199 | | 传真: (86-28) | 6739 8001 | | | | 传真: ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2026-016 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 2026 年第三次临时股东会会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无增加、变更提案的情况。 2、本次股东会以现场投票和网络投票相结合的表决方式。 3、本次股东会未涉及变更前次股东会决议的情形。 2、通过网络投票的股东 278 人，代表股份 52,786,695 股，占公司有表决权 股份总数的 11.3117%。 3、通过现场和网络投票的单独或合计持有公司股份比例低于 5%的股东（代 理人）共 278 人，代表股份 3,592,816 股，占公司有表决权股份总数的 0.7699%。 二、议案审议情况 与会股东（代理人）以现场记名投票和网络投票相结合的方式对本次议案进 行了表决，情况如下： 4、中小投资者是指除上市公司董事、高级管理人员以及单独或者合计持有 公司 5%以上股份的股东以外的其他股东。 一 ...

Core Viewpoint - The diagnostic reagent industry in China is experiencing fluctuations in market size due to the impact of COVID-19, with a projected recovery and growth expected by 2025, reaching a market size of 140 billion yuan, an 8% increase year-on-year [6][7]. Industry Overview - Diagnostic reagents are essential tools in medicine and biology for detecting diseases, infections, and other medical conditions through interactions with biological samples [4][6]. - The market is primarily dominated by in vitro diagnostic reagents, while in vivo diagnostics remain relatively small [6]. Market Size and Trends - The market for in vitro diagnostic reagents in China has shown an upward trend since 2015, with rapid growth from 2020 to 2022 due to the pandemic, but a 14% decline in 2023 due to reduced demand for COVID-19 diagnostic reagents [6][7]. - The market is expected to recover in 2024, with projections indicating a market size of 140 billion yuan by 2025, reflecting an 8% year-on-year growth [6][7]. Competitive Landscape - The diagnostic reagent market includes both domestic companies like Mindray Medical, Antu Bio, and Wanfu Bio, and international firms such as Roche Diagnostics and Abbott, all competing for market share [8]. - Domestic companies are noted for their strong R&D capabilities and significant market presence [8]. Industry Development Stages - The diagnostic reagent industry in China has progressed through four stages: nascent, initial, extensive development, and rapid growth, with significant advancements in technology and regulatory improvements since the 21st century [5]. Industry Chain - The industry chain consists of upstream raw materials (diagnostic enzymes, antigens, antibodies, etc.), the midstream diagnostic reagent production, and downstream applications in medical institutions and third-party diagnostic organizations [6]. Market Segmentation - The in vitro diagnostic reagent market is segmented, with immunodiagnostic reagents holding a 32% market share, followed by molecular diagnostic reagents at 19%, and biochemical diagnostic reagents at 18% [7]. Future Trends - The industry is expected to focus on high-end product upgrades, with companies increasing R&D investments to enhance product value amidst price pressures from centralized procurement [9]. - There is a trend towards market penetration in lower-tier cities and global expansion, with domestic products entering emerging markets in Southeast Asia and Africa [10]. - The industry is evolving towards a model centered on clinical value and personalized medicine, integrating diagnostic solutions with treatment recommendations [11].

Group 1 - The company Wanfu Biological announced the convening of its 22nd meeting of the fifth board of directors on February 12, 2026, which was held in a hybrid format of in-person and communication [1] - The meeting reviewed the proposal to hold the third temporary shareholders' meeting of 2026 [1] Group 2 - Investors Ge Weidong and Fang Wenyuan have jointly invested 1 billion yuan each in Jianghuai, leading to a significant increase in the company's stock price [1] - Historical analysis indicates that retail investors participating in private placements have experienced both gains and losses [1]

华泰联合证券有限责任公司关于 一、募集资金基本概况 2024 年 3 月 11 日，根据中国证券监督管理委员会出具的《关于同意广州 万孚生物技术股份有限公司向特定对象发行股票注册的批复》（证监许可 [2023]1380 号），公司向特定对象发行人民币普通股合计 27,450,980 股（每股面 值 1 元），每股发行认购价格为人民币 25.50 元，募集资金总额为人民币 699,999,990.00 元。扣除各项发行费用 11,009,741.51 元（含税）后，实际募集 资金净额为人民币 688,990,248.49 元。募投项目拟投入募集资金金额如下： 单位：万元 | 序号 | 项目名称 | 拟投入募集资金 | | | --- | --- | --- | --- | | 1 | 知识城生产基地建设项目 | | 45,000.00 | | 2 | 生物原料研发项目 | | 4,500.00 | | 3 | 补充流动资金 | | 19,399.02 | | | 合计 | | 68,899.02 | 1 二、本次募集资金投资项目变更的有关情况 （一）原募投项目计划和实际投入情况 本次拟变更的原项目为"生物原料研 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2026-014 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于部分募集资金投资项目变更 并将剩余募集资金永久补充流动资金的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）于 2026 年 2 月 12 日 召开第五届董事会第二十二次会议，审议通过了《关于部分募集资金投资项目变 更并将剩余募集资金永久补充流动资金的议案》。本议案是针对 2022 年度向特定 对象发行股份的募集资金投资项目"生物原料研发项目"提出变更。本次变更是 公司为应对国内集采常态化挑战、突破国际高端市场壁垒，并加速从"POCT"向 "IVD"战略跨越而做出的主动战略调整。现将具体情况公告如下： 一、募集资金基本概况 2024 年 3 月 11 日，根据中国证券监督管理委员会出具的《关于同意广州万 孚生物技术股份有限公司向特定对象发行股票注册的批复》（证监许可 [2023]1380 ...